Novo Nordisk : Adjustment to 2024e guidance following recognition of the ocederunone impairment
>Ocedurenone CLARION-CKD trial stopped - Yesterday we learned that the group had decided to halt development of its drug candidate ocedurenone. Ocederunone was currently assessed in a phase III trial ( CLARION-CKD) in patients with uncontrolled hypertension and chronic kidney disease. The trial design called for an interim analysis after all trial participants had completed 12 weeks of treatment. On the basis of this interim analysis, an independent committe...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.